Skip to content
February 20, 2024

Equity.Guru

Investment information for the new generation

Search
Revive Therapeutics

Revive Therapeutics (RVV.C) provides update on Bucillamine formulation development

Revive Therapeutics (RVV.V) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19.

Today, the Company provided an update on the development of a next generation lyophilized formulation of Bucillamine. The Company expects to have its novel lyophilized formulation of Bucillamine ready for production with a contract development manufacturing organization for clinical evaluation in 2024.

At the heart of Revive’s portfolio is Bucillamine, a drug with potential applications in multiple therapeutic areas. Notably, the company has initiated the development of a next-generation formulation of Bucillamine, exploring its potential in new treatment paradigms. This initiative builds on the company’s earlier efforts, where Bucillamine was studied in a Phase 3 clinical trial for the treatment of COVID-19.

 

Under an agreement with the University of Waterloo, formulation development work is ongoing and is expected to be completed by the end of the year. The research team has improved the solubility of Bucillamine and subsequent lyophilization has resulted in more than double enhancement of solubility, which would unlock the therapeutic utility of Bucillamine for public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

The novel Bucillamine formulation could support the continuation of the research project the Company has with the Defence R&D Canada – Suffield, an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure.

 

RVV info chart 1

 

TradingView Chart

The stock is testing its major support zone around $0.025. The stock should see buyers enter here to hold support. A daily close above $0.04 would be a good start for potential upwards momentum. The major resistance zone comes in at the $0.06 zone.

On November 20th 2023, bulls stepped in and printed a strong full bodied engulfing candle. This is a strong sign that buyers are here. If you look to July and August 2023, you can see that engulfing candles have led to bounces back to the $0.06 resistance zone.

Related Posts

More on

Leave a Reply

Your email address will not be published. Required fields are marked *